债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2025-080 深圳康泰生物制品股份有限公司 关于控股股东的一致行动人减持计划预披露的公告 公司控股股东、实际控制人的一致行动人杜兴连女士保证向公司提供信息的内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示: 公司控股股东、实际控制人的一致行动人杜兴连女士持有公司股份 2,724,048 股(占公司总股本比例 0.24%)，计划自本公告披露之日起十五个交易 日后的三个月内（法律法规、规范性文件规定不得进行减持的时间除外），以集 中竞价或大宗交易方式减持公司股份不超过 2,724,048 股（即不超过公司总股本 比例 0.24%）。本次减持计划的实施不会影响公司的治理结构和持续经营，不会 导致公司控制权发生变化。 深圳康泰生物制品股份有限公司（以下简称"公司"）近日收到公司控股股 东、实际控制人的一致行动人杜兴连女士出具的《关于股份减持计划的告知函》， 其因个人资金需要，计划减持公司股份，现将有关情况公告如下： | 股东名称 ...

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].

Group 1 - Shenzhen is recognized as a leading "entrepreneur-friendly city" in China, often referred to as the "ceiling for enterprises" [1] - The city established the first official "Entrepreneur Day" in the country, celebrated annually on November 1 since 2019, highlighting its commitment to supporting entrepreneurs [2] - During this year's "Entrepreneur Day," Shenzhen awarded 60 business leaders the title of "Outstanding Builders of Socialism with Chinese Characteristics in Non-Public Economy" and recognized 30 companies with the "Shenzhen Contribution Award" [2][5] Group 2 - The list of awardees includes prominent figures from various industries, such as technology, finance, and manufacturing, showcasing a diverse representation of Shenzhen's business landscape [3][4] - Shenzhen's private economy is significant, with over 2.7 million private enterprises as of June 2025, contributing approximately 40% of fixed asset investment, over 50% of tax revenue, nearly 60% of GDP, and over 70% of import and export volume [6] - The city is home to 10 companies listed in the 2025 Fortune Global 500, indicating its strong economic presence and the prominence of private enterprises [6] Group 3 - Shenzhen's success as a hub for entrepreneurs is attributed to its innovative policies and a culture that encourages risk-taking and supports failure [8][10] - The city has a well-developed industrial chain and an active capital market, which further enhances its attractiveness for business development [10] - The inclusive spirit of Shenzhen, encapsulated in the phrase "Once you come, you are a Shenzhen person," draws talent from across the country [9]

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

Core Viewpoint - Kangtai Biological (300601) has announced the initiation of Phase I clinical trials for its quadrivalent influenza virus split vaccine targeting the 6-35 month age group, with the first subject successfully enrolled [1] Group 1 - The company has completed preparations for the Phase I clinical trial of the quadrivalent influenza vaccine [1] - The clinical trial is now officially underway following the successful enrollment of the first participant [1]

Core Viewpoint - Kangtai Biological (300601.SZ) has initiated Phase I clinical trials for its quadrivalent influenza virus split vaccine targeting the population aged 6 to 35 months, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Development - The quadrivalent influenza virus split vaccine has completed preparations for Phase I clinical trials [1] - The first subject has been successfully enrolled in the Phase I clinical trial [1] Group 2: Vaccine Purpose and Importance - The vaccine is designed to stimulate the immune system to produce immunity against influenza viruses associated with the vaccine strains [1] - Influenza, caused by the influenza virus, is an acute respiratory infectious disease, and vaccination is the most effective and economical measure to prevent influenza and its outbreaks [1]

Core Viewpoint - The company has initiated Phase I clinical trials for its quadrivalent influenza virus split vaccine targeting the 6-35 month age group, with the first subject successfully enrolled [1] Group 1: Vaccine Development - The quadrivalent influenza virus split vaccine is designed to stimulate immunity against influenza viruses associated with vaccine-related strains [1] - The Phase I clinical trial employs a single-center, randomized, blinded, positive-control design to assess the safety and preliminary immunogenicity of the vaccine in the specified age group [1]

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-079 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 深圳康泰生物制品股份有限公司 关于四价流感病毒裂解疫苗（6-35 月龄人群）开启Ⅰ期临床 试验的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 四价流感病毒裂解疫苗（6-35 月龄人群）Ⅰ期临床试验采用单中心、随机、 盲法、阳性对照设计，旨在评价四价流感病毒裂解疫苗在 6-35 月龄人群中接种 的安全性和初步免疫原性。 三、对公司的影响 本次四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验并成功完成 首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的 临床研究，若该疫苗研发成功，将进一步丰富公司产品布局，增强公司的核心竞 争力和市场地位，为公司持续稳健发展奠定坚实基础。 四、风险提示 疫苗研发是一项复杂严谨的科学活动，难度大、周期长，在上市销售前需要 申请临床试验、进行临床试验、申请药品注册批件、产品批签发。目前公司四价 流感病毒裂解疫苗（ ...

Group 1 - The seventh "Shenzhen Entrepreneur Day" is held on November 1, honoring entrepreneurs and promoting the spirit of the 20th Central Committee of the Communist Party of China [1] - A total of 60 individuals are awarded the title of "Outstanding Builders of Socialism with Chinese Characteristics" [1] - 30 companies, including SF Holding Co., Ltd., receive the "Shenzhen Contribution Award for Glorious Undertakings" [3] Group 2 - Notable individuals recognized include Ding Qiangqiang, General Manager of Shenzhen Mofang Satellite Technology Co., Ltd., and Wang Chuanqi, Chairman of Shenzhen Xinhui Catering Service Co., Ltd. [1][2] - The awarded companies span various industries, including logistics, pharmaceuticals, and technology, highlighting the diversity of Shenzhen's economic landscape [3][4]

Core Viewpoint - 康泰生物 is a leading company in the domestic vaccine industry, focusing on the research, production, and sales of human vaccines, with a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, 康泰生物 reported revenue of 2.063 billion yuan, ranking 4th in the industry, with the top competitor, 辽宁成大, achieving 8.114 billion yuan [2] - The net profit for the same period was 49.18 million yuan, ranking 7th in the industry, with 辽宁成大 leading at 1.453 billion yuan [2] - The company’s revenue grew by 2.24% year-on-year, while net profit saw a significant decline of 86% [6] Group 2: Financial Ratios - As of Q3 2025, 康泰生物's debt-to-asset ratio was 32.01%, higher than the industry average of 27.82% [3] - The gross profit margin for Q3 2025 was 73.82%, exceeding the industry average of 63.72% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 3.15% to 63,400 [5] - The average number of circulating A-shares held per shareholder decreased by 2.99% to 14,200 [5] Group 4: Executive Compensation - The chairman, 杜伟民, received a salary of 3.5075 million yuan in 2024, a slight decrease from the previous year [4] - The president, 苗向, saw an increase in salary to 3.5131 million yuan in 2024, up from 3.4988 million yuan [4] Group 5: International Expansion - 康泰生物 has been advancing its international strategy, with overseas revenue reaching 41.9 million yuan in Q3 2025, a year-on-year increase of 324.27% [6] - The company has established partnerships for multiple vaccines in over 20 countries [6]